Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients

[1]  M. Kudo.  Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy , 2021, Liver Cancer.

[2]  L. Eusebi,et al.  Non-invasive tests for the prediction of primary hepatocellular carcinoma , 2020, World journal of gastroenterology.

[3]  G. Stark,et al.  Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis , 2020, Nature Communications.

[4]  Y. Ye,et al.  The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis , 2020, PloS one.

[5]  Y. Koyama,et al.  IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. , 2019, Journal of hepatology.

[6]  Jiayin Yang,et al.  Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China , 2019, Medicine.

[7]  G. Su,et al.  Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients , 2019, Digestive Diseases and Sciences.

[8]  Hongqin Xu,et al.  Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[9]  S. Gaffen,et al.  IL-17 receptor–based signaling and implications for disease , 2019, Nature Immunology.

[10]  J. Kim,et al.  Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis , 2018, Medicine.

[11]  Bin Zhang,et al.  Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer , 2018, Oncoimmunology.

[12]  N. Caporaso,et al.  Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows , 2018, World journal of gastroenterology.

[13]  G. Marasco,et al.  Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[14]  D. Sinn,et al.  Non‐invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low‐level viremia , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[15]  R. Oulton,et al.  Unusual scaling laws for plasmonic nanolasers beyond the diffraction limit , 2017, Nature Communications.

[16]  A. Rajnicek,et al.  The potential of Antheraea pernyi silk for spinal cord repair , 2017, Scientific Reports.

[17]  A. Ghaderi,et al.  Interleukin-18: a regulator of cancer and autoimmune diseases , 2017, European Cytokine Network.

[18]  R. Ransohoff,et al.  IL-17 induced NOTCH1 activation in oligodendrocyte progenitor cells enhances proliferation and inflammatory gene expression , 2017, Nature Communications.

[19]  T. Gamblin,et al.  Prognostic significance of baseline alpha-fetoprotein in hepatocellular carcinoma: systematic review and meta-analysis , 2017 .

[20]  Kwang-Huei Lin,et al.  A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients , 2017, Scientific Reports.

[21]  A. Bhardwaj,et al.  In situ click chemistry generation of cyclooxygenase-2 inhibitors , 2017, Nature Communications.

[22]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[23]  C. Tiribelli,et al.  Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis , 2016, World journal of gastroenterology.

[24]  A. Waisman,et al.  Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma. , 2016, Cancer cell.

[25]  C. Ki,et al.  Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. , 2015, Annals of hepatology.

[26]  T. Murakami,et al.  Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe , 2015, Liver Cancer.

[27]  Chia-Yang Hsu,et al.  Using Serum α-Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff? , 2015, PloS one.

[28]  Wim Van Biesen,et al.  Diagnosis and treatment of hyponatremia: a systematic review of clinical practice guidelines and consensus statements , 2014, BMC Medicine.

[29]  I. Abdelgawad.  Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients , 2014, Journal of Clinical Pathology.

[30]  Yugang Wang,et al.  Function of interleukin-17 and −35 in the blood of patients with hepatitis B-related liver cirrhosis , 2014, Molecular medicine reports.

[31]  Mohsen Naghavi,et al.  Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis , 2014, BMC Medicine.

[32]  A. Cucchetti,et al.  Prognostic factors for hepatocellular carcinoma recurrence. , 2014, World journal of gastroenterology.

[33]  K. Sikaris,et al.  The de ritis ratio: the test of time. , 2013, The Clinical biochemist. Reviews.

[34]  S. Rutz,et al.  IL‐22, not simply a Th17 cytokine , 2013, Immunological reviews.

[35]  Shi-jun Chen,et al.  Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection , 2013, Diagnostic Pathology.

[36]  S. Qiu,et al.  High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma , 2013, Journal of experimental & clinical cancer research : CR.

[37]  G. Gao,et al.  Correlation of microrna-372 upregulation with poor prognosis in human glioma , 2013, Diagnostic Pathology.

[38]  Ying Wang,et al.  Elevated Pretherapy Serum IL17 in Primary Hepatocellular Carcinoma Patients Correlate to Increased Risk of Early Recurrence after Curative Hepatectomy , 2012, PloS one.

[39]  Hushan Yang,et al.  As submitted to : European Journal of Cancer And later published as : Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection – Results from a clinic-based longitudinal cohort , 2018 .

[40]  S. Sookoian,et al.  Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. , 2012, World journal of gastroenterology.

[41]  Qing Zhao,et al.  Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C , 2012, Journal of gastroenterology and hepatology.

[42]  M. Fiorentino,et al.  OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation , 2011, Virchows Archiv.

[43]  L. Bonomo,et al.  Usefulness of Ultrasound Imaging in Detecting Psoriatic Arthritis of Fingers and Toes in Patients with Psoriasis , 2011, Clinical & developmental immunology.

[44]  F. Tacke,et al.  Role of IL-17 and Th17 Cells in Liver Diseases , 2010, Clinical & developmental immunology.

[45]  P. Zhou,et al.  The Role of T-Helper 17 (Th17) Cells in Patients with Medulloblastoma , 2010, The Journal of international medical research.

[46]  D. Vergani,et al.  Aetiopathogenesis of autoimmune hepatitis. , 2010, Journal of autoimmunity.

[47]  Jiyuan Zhang,et al.  Interleukin‐17–producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B , 2010, Hepatology.

[48]  J. Xu,et al.  Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. , 2009, Journal of Hepatology.

[49]  A. Fischer.  Human immunodeficiency: Connecting STAT3, Th17 and human mucosal immunity , 2008, Immunology and cell biology.

[50]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[51]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[52]  Adrian M Di Bisceglie,et al.  Diagnosis of hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[53]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[54]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[55]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[56]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.